AU2011227613B2 - Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport - Google Patents

Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport Download PDF

Info

Publication number
AU2011227613B2
AU2011227613B2 AU2011227613A AU2011227613A AU2011227613B2 AU 2011227613 B2 AU2011227613 B2 AU 2011227613B2 AU 2011227613 A AU2011227613 A AU 2011227613A AU 2011227613 A AU2011227613 A AU 2011227613A AU 2011227613 B2 AU2011227613 B2 AU 2011227613B2
Authority
AU
Australia
Prior art keywords
formulation
dapsone
aerosolized
lps
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011227613A
Other languages
English (en)
Other versions
AU2011227613A1 (en
Inventor
Soichiro Kanoh
Bruce K. Rubin
Tsuyoshi Tanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of AU2011227613A1 publication Critical patent/AU2011227613A1/en
Application granted granted Critical
Publication of AU2011227613B2 publication Critical patent/AU2011227613B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011227613A 2010-03-15 2011-03-08 Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport Ceased AU2011227613B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31387710P 2010-03-15 2010-03-15
US61/313,877 2010-03-15
US41635310P 2010-11-23 2010-11-23
US61/416,353 2010-11-23
PCT/US2011/027494 WO2011115778A2 (en) 2010-03-15 2011-03-08 Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport

Publications (2)

Publication Number Publication Date
AU2011227613A1 AU2011227613A1 (en) 2012-10-04
AU2011227613B2 true AU2011227613B2 (en) 2015-09-03

Family

ID=44649767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011227613A Ceased AU2011227613B2 (en) 2010-03-15 2011-03-08 Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport

Country Status (8)

Country Link
US (3) US20130005822A1 (enExample)
EP (1) EP2547335A4 (enExample)
JP (1) JP5908884B2 (enExample)
KR (1) KR101924162B1 (enExample)
AU (1) AU2011227613B2 (enExample)
BR (1) BR112012023877A2 (enExample)
CA (1) CA2793170C (enExample)
WO (1) WO2011115778A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1206995A1 (en) 2012-04-06 2016-01-22 The Uab Research Foundation Methods for increasing cftr activity
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物
CA3126367A1 (en) * 2020-03-30 2021-09-30 Pulmonem Inc. Dapsone formulations and methods of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085146A1 (en) * 2000-05-12 2001-11-15 Astrazeneca Ab Pharmaceutical compounds for treating copd
WO2005041864A2 (en) * 2003-10-21 2005-05-12 Pharmacia Corporation Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
DE69530325T2 (de) 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
GB9820886D0 (en) 1998-09-26 1998-11-18 Glaxo Group Ltd Inhalation device
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US7077130B2 (en) 2000-12-22 2006-07-18 Chrysalis Technologies Incorporated Disposable inhaler system
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
EP1539284B1 (en) 2002-09-06 2020-01-29 Philip Morris Products S.a.s. Aerosol generating device and method for generating aerosols
US7497214B2 (en) 2002-09-16 2009-03-03 3M Innovative Properties Company Aerosol dispensers and adaptors therefor
BR0314552A (pt) * 2002-09-30 2005-08-09 Novartis Ag Métodos para prognosticar elevações de colesterol durante terapia imunossupressora
US20040086469A1 (en) * 2002-10-30 2004-05-06 Osborne David W. Protectant for UV-induced skin damage
US7683029B2 (en) 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US8586010B2 (en) * 2008-02-27 2013-11-19 Allergan, Inc. Dapsone to treat rosascea
WO2010099523A1 (en) * 2009-02-27 2010-09-02 University Of Cincinnati Method of treating reactive airway disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085146A1 (en) * 2000-05-12 2001-11-15 Astrazeneca Ab Pharmaceutical compounds for treating copd
WO2005041864A2 (en) * 2003-10-21 2005-05-12 Pharmacia Corporation Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method

Also Published As

Publication number Publication date
EP2547335A2 (en) 2013-01-23
US20180243213A1 (en) 2018-08-30
CA2793170C (en) 2018-04-17
KR20130055580A (ko) 2013-05-28
CA2793170A1 (en) 2011-09-22
AU2011227613A1 (en) 2012-10-04
BR112012023877A2 (pt) 2016-08-02
JP2013522295A (ja) 2013-06-13
KR101924162B1 (ko) 2018-11-30
EP2547335A4 (en) 2014-04-16
JP5908884B2 (ja) 2016-04-26
WO2011115778A9 (en) 2012-01-12
WO2011115778A2 (en) 2011-09-22
US20150040894A1 (en) 2015-02-12
US20130005822A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
AU2007297691B2 (en) Pulmonary surfactant formulations and methods for promoting mucus clearance
CN104203267A (zh) 用于治疗流感和副流感患者的方法、化合物和组合物
Kanoh et al. Dapsone inhibits IL-8 secretion from human bronchial epithelial cells stimulated with lipopolysaccharide and resolves airway inflammation in the ferret
US5863563A (en) Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US20180243213A1 (en) Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
WO1996012470A9 (en) Treatment of pulmonary conditions associated with insufficient secretion of surfactant
CN112533589A (zh) 用于治疗粘液高分泌的含有粘液溶解剂的组合物及其给药装置
US20220409627A1 (en) Treatment of lower airways disorders
AU2023270302B2 (en) Method for Reducing Lung Inflammation
US20100092402A1 (en) Treatment of respiratory disease
CN115279357B (zh) 含有羟基脲的抑制炎症反应的药物组合物
CN116437903A (zh) 肝素组合物在通过吸入途径通过软雾吸入器或振动网状技术雾化器治疗病毒性肺病、急性和/或慢性肺病中的用途
Narasimhan et al. New and investigational treatments in cystic fibrosis
CN113599376A (zh) 鸢尾甲黄素a在制备防治支气管哮喘疾病药物中的应用
JP2023520770A (ja) 肺浮腫又は肺炎症を治療するための組成物及び方法
US20230041980A1 (en) Method of protecting a respiratory tract or a lung from damage, method of protecting a lung from pressure damage induced by a ventilator, method of suppressing spread of infection with viruses or bacteria that cause pneumonia in pulmonary bronchial epithelial cells or alveolar epithelial cells, and nasal spray
AU690758C (en) Treatment of pulmonary conditions associated with insufficient secretion of surfactant
Saravanan et al. Section: Anaesthesiology
AU2022261974A1 (en) Compositions of interleukin-1 receptor antagonist
WO2022166724A1 (zh) 一种福多司坦吸入用溶液制剂及其制备方法和用途
HK40087339A (zh) 用於治疗肺水肿或肺炎的组合物和方法
Rau Jr Recent developmentsin respiratory care pharmacology
Daviskas et al. Drug therapies that augment airway surface liquid
US20170020838A1 (en) Treatment for respiratory disease
Haghi et al. Human Stimulus Factor Is a Promising Peptide for Delivery of

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired